GlaxoSmithKline (GSK), through its Together with GSK Oncology program, provides claims assistance, access, and reimbursement support services for its oncology drugs (Table).
Eligible patients with commercial insurance may receive assistance with their out-of-pocket expenses for Zejula, Blenrep, or Jemperli, including up to $100 per administration for intravenous drugs, for a total annual limit of $26,000. Patients may be eligible if they:
Uninsured patients who meet eligibility requirements may access medication free of charge through GSK’s Patient Assistance Program. Medicare patients who meet specific program requirements may also be eligible for this program.
To qualify for the Zejula, Blenrep, or Jemperli Patient Assistance Program, a patient must:
For assistance with the Zejula, Blenrep, or Jemperli Patient Assistance Program, please call Together with GSK Oncology at 844-447-5662. Click here to review program terms and conditions.
Blenrep is available only through the Blenrep REMS (Risk Evaluation and Mitigation Strategy), a restricted distribution program to help manage the risk of ocular toxicity. The Ophthalmology Support Services program helps eligible, enrolled patients who are taking Blenrep locate an eye care professional, schedule an eye care appointment, and provide reminders for scheduled eye care appointments. To learn more, call Together with GSK Oncology at 844-447-5662.
For patients experiencing delay in coverage at first dispense of Zejula (Quick Start) or coverage interruptions while already on treatment (Bridge), download and fill out the enrollment form, then fax to Together with GSK Oncology at 800-645-9043 to check for eligibility. Click here to access the form.
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?
Help us fix it! Report broken links here.
Report Broken Links
Submit